Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers Followed by Open Label Treatment in Patients With PNH to Evaluate the Safety, Tolerability, PK and PD of ADX-038

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy volunteers (HV) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Study Overview

• Status: Not yet recruiting
• Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Intervention / Treatment: Drug: Placebo; Drug: ADX-038

Detailed Description

The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-038.

The study consists of 2 parts:

1. Part A - Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 5 dose cohorts.
2. Part B - Expansion cohort in participants with paroxysmal nocturnal hemoglobinuria (PNH) at selected dose from Part A and will be open label.

• Study Type: Interventional
• Enrollment (Estimated): 53
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Richard Friend, MD; Phone Number: +61 403 415 925; Email: [email protected]

Study Locations

• Australia
  • Queensland
    • Brisbane, Queensland, Australia, 4006
      • Nucleus Network Brisbane
      • Contact: Richard Friend, MD; Phone Number: +61 403 415 925; Email: [email protected]

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

1. Male and female adults 18 to 55 years old
2. Body mass index (BMI) between 18 and 32 kg/m2
3. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
4. Willing and able to provide informed consent and comply with all study visits and procedures
5. Negative urine drug, nicotine/tobacco, and breath alcohol test result
6. Neisseria meningitis vaccination
7. Pneumococcus vaccination
8. Hemophilus influenzae vaccination Exclusion Criteria
9. Any significant medical history
10. Active malignancy and/or history of malignancy in the past 5 years
11. History of liver disease, Gilbert's syndrome, or abnormal liver function test
12. Estimated creatinine clearance <60 mL/min using the Cockcroft-Gault formula
13. Any active infection or acute illness
14. History of meningococcal infection or frequent respiratory, nasopharyngeal or ear infections
15. History of previous or current tuberculosis infection.
16. Prior splenectomy
17. Major surgery or significant traumatic injury occurring within 3 months
18. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion
19. Positive serology tests for human immunodeficiency virus hepatitis B surface antigen or hepatitis C virus
20. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication
21. Treatment with another investigational product within 30 days
22. Known any clinically significant allergic reactions
23. Known hypersensitivity to any of the study drug ingredients or penicillin.
24. History or presence of alcohol
25. Blood donation
26. Pregnancy

27. May have a higher risk to be exposed to infected individuals, for example active healthcare employees.

    Criteria (Part B) Inclusion Criteria

28. Male and female adults 18-65 years old
29. Confirmed diagnosis of PNH based on documented clone size of PNH blood cells by flow cytometry.
30. Serum LDH levels are at least 1.25-fold above the ULN for non-treated participants
31. Liver function test values are less than 2x ULN
32. Mean hemoglobin (Hb) <12 g/dL.
33. A history of red blood cell transfusion within at least 3 months
34. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, at screening.
35. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
36. Willing and able to provide informed consent and comply with all study visits and procedures
37. Neisseria meningitis vaccination
38. Pneumococcus vaccination

39. Hemophilus influenzae vaccination

    Exclusion Criteria

40. Known or suspected hereditary or acquired complement deficiency
41. History of clinically significant arterial or venous thrombosis
42. History of hematopoietic stem cell transplantation
43. History of meningococcal infection
44. Any significant medical history
45. Active malignancy and/or history of malignancy in the past 5 years
46. Any active viral, bacterial, parasitic, or fungal infection or acute illness
47. Any evidence of sero-positive autoimmune connective tissue diseases
48. Any evidence of active inflammatory conditions
49. History of previous or current tuberculosis infection.
50. Prior splenectomy
51. Major surgery or significant traumatic injury occurring within 3 months
52. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion
53. Inadequate organ function
54. Positive serology tests for human immunodeficiency virus hepatitis B surface antigen or hepatitis C virus
55. Willing to continue after enrollment with their current treatment with a complement inhibitor.
56. Use of vaccines, or changes in any prescription, supplements/vitamins, or over-the counter medication
57. Treatment with another investigational product or biologic agent within 30 days
58. Blood donation within 30 days
59. Pregnancy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PART A - Active ADX-038 administered to HV; For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.	Drug: ADX-038; siRNA duplex oligonucleotide; Other Names: siRNA
Placebo Comparator: PART A- Placebo administered to HV; For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.	Drug: Placebo; Saline; Other Names: Saline
Experimental: PART B - ADX-038 administered to PNH participants; This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.	Drug: ADX-038; siRNA duplex oligonucleotide; Other Names: siRNA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety in Healthy Volunteers	To evaluate the safety and tolerability of ADX-038 in HVs by incidence, relationship, and severity of adverse events and serious adverse events	365 days
Safety in Healthy Volunteers	To evaluate the safety and tolerability of ADX-038 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)	365 days
Safety in Paroxysmal Nocturnal Hemoglobinuria	To evaluate the safety and tolerability of ADX-038 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)	365 days
Safety in Paroxysmal Nocturnal Hemoglobinuria	To evaluate the safety and tolerability of ADX-038 in HAE by incidence, relationship, and severity of adverse events and serious adverse events	365 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Maximum observed concentration (Cmax)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Maximum observed concentration (Cmax)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Time to Cmax (Tmax)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Time to Cmax (Tmax)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Area under the concentration-time curve from 0 to infinity (AUC0-∞)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Area under the concentration-time curve from 0 to infinity (AUC0-∞)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Apparent terminal half-life (t½)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs by measuring the Apparent terminal half-life (t½)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Terminal elimination rate constant (λz)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Terminal elimination rate constant (λz)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Total apparent body clearance (CL/F)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Total apparent body clearance (CL/F)	8 days
Pharmacokinetics in Healthy Volunteers	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Apparent volume of distribution (Vz/F)	8 days
Pharmacokinetics in Paroxysmal Nocturnal Hemoglobinuria	To characterize the Pharmacokinetics of ADX-038 in HVs measuring the Apparent volume of distribution (Vz/F)	8 days
Pharmacodynamics in Healthy Volunteers	Change from base in plasma concentrations over time in Complement factor B (CFB) protein	365 days
Pharmacodynamics in Paroxysmal Nocturnal Hemoglobinuria	Change from base in plasma concentrations over time in Complement factor B (CFB) protein	365 days
Pharmacodynamics in Healthy Volunteers	Change from base in plasma concentrations over time in change in complement alternative pathway activity via assay measurement	365 days
Pharmacodynamics in Paroxysmal Nocturnal Hemoglobinuria	Change from base in plasma concentrations over time in change in complement alternative pathway activity via assay measurement	365 days
Pharmacodynamics in Paroxysmal Nocturnal Hemoglobinuria	Change from baseline in lactate dehydrogenase	365 days
Pharmacodynamics in Paroxysmal Nocturnal Hemoglobinuria	Change from baseline in total hemoglobin	365 days

Collaborators and Investigators

• Sponsor: ADARx Pharmaceuticals, Inc.
• Collaborators: ADARx Australia Pty Ltd

Study record dates

Study Major Dates

• Study Start (Estimated): June 30, 2023
• Primary Completion (Estimated): November 30, 2024
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: May 17, 2023
• First Submitted That Met QC Criteria: May 17, 2023
• First Posted (Actual): May 25, 2023

Study Record Updates

• Last Update Posted (Actual): May 25, 2023
• Last Update Submitted That Met QC Criteria: May 17, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: PNH; siRNA
• Additional Relevant MeSH Terms: Urologic Diseases; Urological Manifestations; Bone Marrow Diseases; Hematologic Diseases; Urination Disorders; Anemia; Proteinuria; Anemia, Hemolytic; Myelodysplastic Syndromes; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Hemoglobinuria; Hemoglobinuria, Paroxysmal
• Other Study ID Numbers: ADX-038-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No